Kronos Bio Inc. (KRON) News
Filter KRON News Items
KRON News Results
|Loading, please wait...|
KRON News Highlights
- KRON's 30 day story count now stands at 3.
- Over the past 24 days, the trend for KRON's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and KB are the most mentioned tickers in articles about KRON.
Latest KRON News From Around the Web
Below are the latest news stories about Kronos Bio Inc that investors may wish to consider to help them evaluate KRON as an investment opportunity.
Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib trial to start in Q1 2022; Phase 3 registrational AGILITY trial of entospletinib underway, with results anticipated in the second half of 2023 $339.5 million in cash, cash equivalents and investments as of December 31, 2021, providing expected runway into the second half of 2024 SAN MATEO, Calif. and CA
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development. Dr. Olek joins Kronos Bio from Loxo Oncology at Lilly. Dr. Olek will be responsible for the planning, conduct and analysis of Kronos Bio’s clinical trials, reporting to Jorge DiMa
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Kronos Bio, Inc. (NASDAQ:KRON) shares gapped down before the market opened on Tuesday . The stock had previously closed at $14.00, but opened at $13.70. Kronos Bio shares last traded at $14.66, with a volume of 1,131 shares trading hands. Several analysts recently commented on KRON shares. Zacks Investment Research raised Kronos Bio from a […] The post Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00 appeared first on ETF Daily News .
Kronos Bio, Inc. (NASDAQ:KRON) VP Jorge Dimartino sold 16,402 shares of the firms stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $12.37, for a total value of $202,892.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through 
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million, and included strong support from both new and existing limited partners. With Fund VII, the firm will continue to execute on its strategy
Oncorus (NASDAQ:ONCR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 79.6% of Oncorus shares are held by institutional investors. Comparatively, 68.3% of 
Kronos Bio, Inc. (NASDAQ:KRON) CEO Norbert W. Bischofberger acquired 14,356 shares of the firms stock in a transaction dated Monday, December 6th. The stock was bought at an average cost of $12.09 per share, with a total value of $173,564.04. The transaction was disclosed in a document filed with the SEC, which is available at 
President & CEO of Kronos Bio Inc (30-Year Financial, Insider Trades) Norbert W Bischofberger (insider trades) bought 14,356 shares of KRON on 12/06/2021 at an average price of $12.09 a share.
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
Data in the second half of 2023 could potentially lead to accelerated approval If approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for intensive induction